RenovoRx, Inc.
RNXT· Nasdaq
Released Mar 30, 2026, after the close
10-K filed Mar 30, 2026, 89 days after period end · 0001193125-26-131928
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $238.00K | — | — | — |
| Net Income | -$2.94M |
RenovoRx, Inc. · CIK 1574094 · Engraved from SEC EDGAR
| -$2.88M |
| -$3.23M |
| -$2.16M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.